Leslie Citrome

Summary

Affiliation: Nathan Kline Institute
Country: USA

Publications

  1. ncbi Commentary: bipolar disorder is a potentially fatal disease
    Leslie Citrome
    New York State University School of Medicine, New York
    Postgrad Med 117:9-11. 2005
  2. ncbi Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion
    Leslie Citrome
    New York University School of Medicine, New York City, NY, USA
    Expert Opin Drug Metab Toxicol 6:1551-64. 2010
  3. ncbi Schizophrenia, obesity, and antipsychotic medications: what can we do?
    Leslie Citrome
    New York University School of Medicine, Department of Psychiatry, and the Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
    Postgrad Med 120:18-33. 2008
  4. ncbi Antipsychotics for the treatment of schizophrenia: likelihood to be helped or harmed, understanding proximal and distal benefits and risks
    Leslie Citrome
    New York University School of Medicine, Department of Psychiatry, and the Nathan S Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA
    Expert Rev Neurother 8:1079-91. 2008
  5. ncbi Loss aversion in schizophrenia
    Fabien Tremeau
    Nathan S Kline Institute for Psychiatric Research, Orangeburg, New York 10962, United States
    Schizophr Res 103:121-8. 2008
  6. ncbi Current guidelines and their recommendations for prolactin monitoring in psychosis
    Leslie Citrome
    New York University School of Medicine, Department of Psychiatry, and the Nathan S Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA
    J Psychopharmacol 22:90-7. 2008
  7. ncbi Did CATIE influence antipsychotic use?
    Leslie Citrome
    Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
    Psychiatr Serv 59:476. 2008
  8. ncbi Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety
    Leslie Citrome
    Department of Psychiatry, New York University School of Medicine, and the Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
    J Clin Psychiatry 68:1876-85. 2007
  9. ncbi The effectiveness criterion: balancing efficacy against the risks of weight gain
    Leslie Citrome
    Department of Psychiatry, New York University School of Medicine, New York, USA
    J Clin Psychiatry 68:12-7. 2007
  10. ncbi Introduction: weighing the evidence: weight management insights for treating major mental illness
    Leslie Citrome
    Department of Psychiatry, New York University School of Medicine, New York, USA
    J Clin Psychiatry 68:4. 2007

Detail Information

Publications84

  1. ncbi Commentary: bipolar disorder is a potentially fatal disease
    Leslie Citrome
    New York State University School of Medicine, New York
    Postgrad Med 117:9-11. 2005
  2. ncbi Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion
    Leslie Citrome
    New York University School of Medicine, New York City, NY, USA
    Expert Opin Drug Metab Toxicol 6:1551-64. 2010
    ..Iloperidone is a newly commercialized second-generation (atypical) antipsychotic approved for the acute treatment of schizophrenia in adults...
  3. ncbi Schizophrenia, obesity, and antipsychotic medications: what can we do?
    Leslie Citrome
    New York University School of Medicine, Department of Psychiatry, and the Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
    Postgrad Med 120:18-33. 2008
    ..At the very least, a "small-steps approach" to managing weight should be offered to all patients who are overweight or obese...
  4. ncbi Antipsychotics for the treatment of schizophrenia: likelihood to be helped or harmed, understanding proximal and distal benefits and risks
    Leslie Citrome
    New York University School of Medicine, Department of Psychiatry, and the Nathan S Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA
    Expert Rev Neurother 8:1079-91. 2008
    ..The examples provided are extensions to the initially published NNT and NNH analyses conducted by the first author...
  5. ncbi Loss aversion in schizophrenia
    Fabien Tremeau
    Nathan S Kline Institute for Psychiatric Research, Orangeburg, New York 10962, United States
    Schizophr Res 103:121-8. 2008
    ..Loss aversion is conceived as an affective interference in cognitive processes such as judgment and decision-making. Loss aversion in non-risky choices has not been studied in schizophrenia...
  6. ncbi Current guidelines and their recommendations for prolactin monitoring in psychosis
    Leslie Citrome
    New York University School of Medicine, Department of Psychiatry, and the Nathan S Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA
    J Psychopharmacol 22:90-7. 2008
    ..These decisions would be within the context of considering other adverse events as well as the overall effectiveness of the antipsychotic medication being used...
  7. ncbi Did CATIE influence antipsychotic use?
    Leslie Citrome
    Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
    Psychiatr Serv 59:476. 2008
  8. ncbi Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety
    Leslie Citrome
    Department of Psychiatry, New York University School of Medicine, and the Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
    J Clin Psychiatry 68:1876-85. 2007
    ..To compare the efficacy and safety of the intramuscular formulations of ziprasidone, olanzapine, and aripiprazole in treating agitation...
  9. ncbi The effectiveness criterion: balancing efficacy against the risks of weight gain
    Leslie Citrome
    Department of Psychiatry, New York University School of Medicine, New York, USA
    J Clin Psychiatry 68:12-7. 2007
    ..Predictors of weight gain for olanzapine are reviewed for schizophrenia and bipolar disorder, as is a monitoring plan applicable for all patients receiving antipsychotic therapy...
  10. ncbi Introduction: weighing the evidence: weight management insights for treating major mental illness
    Leslie Citrome
    Department of Psychiatry, New York University School of Medicine, New York, USA
    J Clin Psychiatry 68:4. 2007
  11. ncbi Reducing inpatient aggression: does paying attention pay off?
    Karen A Nolan
    Nathan S Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA
    Psychiatr Q 79:91-5. 2008
    ..Video technology can improve detection, but is labor-intensive and costly. We examined the effectiveness of interventions to improve reporting on a secure inpatient research unit equipped with audio/video surveillance...
  12. ncbi Atypical antipsychotics, elderly patients, and mortality risk
    Leslie Citrome
    New York University School of Medicine and Nathan S. Kline Institute for Psychiatric Research, Orangeburg, New York 10962, USA
    South Med J 100:964-5. 2007
  13. ncbi Risperidone alone versus risperidone plus valproate in the treatment of patients with schizophrenia and hostility
    Leslie Citrome
    Nathan S Kline Institute for Psychiatric Research, Orangeburg, New York 10962, USA
    Int Clin Psychopharmacol 22:356-62. 2007
    ..In conclusion, although patients receiving combination treatment were more likely to complete the study, we were unable to detect a meaningful advantage for combination therapy as measured by rating scales...
  14. ncbi Show me the evidence: using number needed to treat
    Leslie Citrome
    Department of Psychiatry, New York University School of Medicine, USA
    South Med J 100:881-4. 2007
    ....
  15. ncbi Pharmacokinetics of aripiprazole and concomitant carbamazepine
    Leslie Citrome
    Nathan S Kline Institute for Psychiatric Research and Rockland Psychiatric Center, Orangeburg, NY 10962, USA
    J Clin Psychopharmacol 27:279-83. 2007
    ..Additional dose increases should be based on clinical evaluation. When carbamazepine is withdrawn from combination therapy, aripiprazole dose should then be reduced...
  16. ncbi Datapoints: The ups and downs of dosing second-generation antipsychotics
    Leslie Citrome
    Department of Psychiatry, New York University School of Medicine, New York City, USA
    Psychiatr Serv 58:11. 2007
  17. ncbi Incidence, prevalence, and surveillance for diabetes in New York State psychiatric hospitals, 1997-2004
    Leslie Citrome
    Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
    Psychiatr Serv 57:1132-9. 2006
    ....
  18. ncbi A new rating scale for negative symptoms: the Motor-Affective-Social Scale
    Fabien Tremeau
    Clinical Research and Evaluation Facility, Nathan S Kline Institute for Psychiatric Research and Rockland Psychiatric Center, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA
    Psychiatry Res 160:346-55. 2008
    ..Future research that includes the use of the MASS with other patient populations and that investigates the scale's sensitivity during clinical trials should be performed...
  19. ncbi Public-academic partnerships: integrating state psychiatric hospital treatment and clinical research
    Leslie Citrome
    Nathan S Kline Institute forPsychiatric Research, 140 Old Orangeburg Rd, Orangeburg, NY 10962, USA
    Psychiatr Serv 59:958-60. 2008
    ..Kline Institute for Psychiatric Research, colocated on the same campus as Rockland Psychiatric Center, each of which is an independent facility operated by the New York State Office of Mental Health...
  20. ncbi Adjunctive lithium and anticonvulsants for the treatment of schizophrenia: what is the evidence?
    Leslie Citrome
    New York University School of Medicine, Department of Psychiatry, New York, USA
    Expert Rev Neurother 9:55-71. 2009
    ....
  21. ncbi Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed
    Leslie Citrome
    Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
    Postgrad Med 122:39-48. 2010
    ..To describe the efficacy and safety of adjunctive aripiprazole, olanzapine, and quetiapine for major depressive disorder...
  22. ncbi Ziprasidone HCl capsules for the adjunctive maintenance treatment of bipolar disorder in adults
    Leslie Citrome
    Nathan S Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA
    Expert Rev Neurother 10:1031-7. 2010
    ..e., more robust) NNT for quetiapine in terms of proportions of subjects experiencing a mood event (NNT: 4), but a higher incidence of bodyweight gain of at least 7% from baseline...
  23. ncbi Spirituality, schizophrenia, and state hospitals: program description and characteristics of self-selected attendees of a spirituality therapeutic group
    Nadine Revheim
    Nathan S Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA
    Psychiatr Q 81:285-92. 2010
    ..These findings lend support for offering spirituality groups and positive coping during recovery from psychiatric disabilities...
  24. ncbi Citability of original research and reviews in journals and their sponsored supplements
    Leslie Citrome
    Department of Psychiatry, New York University School of Medicine, New York, New York, United States of America
    PLoS ONE 5:e9876. 2010
    ..It is unknown if their contents are cited as often. The objective of this study was to quantify the citability of original research and reviews contained in supplements and compare it with that for the parent journal...
  25. ncbi Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities
    Leslie Citrome
    Nathan S Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA
    Schizophr Res 119:153-9. 2010
    ..This study aimed to characterize the inpatient utilization of depot antipsychotics...
  26. ncbi Impact of real-world ziprasidone dosing on treatment discontinuation rates in patients with schizophrenia or bipolar disorder
    Leslie Citrome
    Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY, USA
    Schizophr Res 115:115-20. 2009
    ..The purpose of this study is to evaluate the relationship between maximum dose of ziprasidone and time to discontinuation in the treatment of schizophrenia/schizoaffective disorder and bipolar disorder in clinical practice...
  27. ncbi Using oral ziprasidone effectively: the food effect and dose-response
    Leslie Citrome
    Department of Psychiatry, Nathan S Kline Institute for Psychiatric Research, New York University School of Medicine, Orangeburg, NY 10962, USA
    Adv Ther 26:739-48. 2009
    ..Provided that an adequate dose of ziprasidone is prescribed, and administered with a 500 kcal meal, ziprasidone can be effectively used to control symptoms without the long-term liabilities of metabolic side effects...
  28. ncbi How dosing of ziprasidone in a state hospital system differs from product labeling
    Leslie Citrome
    Nathan S Kline Institute for Psychiatric Research, Orangeburg, N Y 10962, USA
    J Clin Psychiatry 70:975-82. 2009
    ....
  29. ncbi Olanzapine dosing above the licensed range is more efficacious than lower doses: fact or fiction?
    Leslie Citrome
    Nathan S Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA
    Expert Rev Neurother 9:1045-58. 2009
    ..This is somewhat supported by double-blind, controlled clinical trial evidence, but only for selected patients with severe and/or persistent symptoms...
  30. ncbi Quantifying risk: the role of absolute and relative measures in interpreting risk of adverse reactions from product labels of antipsychotic medications
    Leslie Citrome
    New York University School of Medicine, Department of Psychiatry, and Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
    Curr Drug Saf 4:229-37. 2009
    ..This supplements, but does not replace, information reported directly in clinical trial reports...
  31. ncbi Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response
    Jean Pierre Lindenmayer
    New York University School of Medicine, New York, N Y 10035, USA
    J Clin Psychiatry 70:990-6. 2009
    ..To examine the impact of medication nonadherence on treatment outcome in schizophrenia and potential risk factors for nonadherence...
  32. ncbi Olanzapine plasma concentrations after treatment with 10, 20, and 40 mg/d in patients with schizophrenia: an analysis of correlations with efficacy, weight gain, and prolactin concentration
    Leslie Citrome
    Clinical Research and Evaluation Facility, Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
    J Clin Psychopharmacol 29:278-83. 2009
    ..In conclusion, olanzapine pharmacokinetics of doses up to 40 mg/d was generally consistent with prior findings in studies with fewer subjects and/or lower doses...
  33. ncbi Staff and patient views of the reasons for aggressive incidents: a prospective, incident-based study
    Karen A Nolan
    Clinical Research Division, Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY, 10962, USA
    Psychiatr Q 80:167-72. 2009
    ..Responses to aggressive events do not take causes into account. It is possible that consideration of the reasons for the aggressive behavior might yield more targeted interventions...
  34. ncbi Effect of ziprasidone dose on all-cause discontinuation rates in acute schizophrenia and schizoaffective disorder: a post-hoc analysis of 4 fixed-dose randomized clinical trials
    Leslie Citrome
    Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
    Schizophr Res 111:39-45. 2009
    ..This study examines the relationship of ziprasidone dose and all-cause discontinuation in randomized clinical trials in patients with an acute exacerbation of schizophrenia or schizoaffective disorder...
  35. ncbi Weight gain, metabolic parameters, and the impact of race in aggressive inpatients randomized to double-blind clozapine, olanzapine or haloperidol
    Menahem Krakowski
    Nathan Kline Institute for Psychiatric Research, Nathan Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, United States
    Schizophr Res 110:95-102. 2009
    ..The goal of this study was to assess the effects of clozapine and olanzapine in comparison to the first-generation agent haloperidol on these metabolic parameters in aggressive patients with schizophrenia...
  36. ncbi Dose trends for second-generation antipsychotic treatment of schizophrenia and bipolar disorder
    Leslie Citrome
    Nathan S Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA
    Schizophr Res 108:238-44. 2009
    ..This has been reported for olanzapine and quetiapine, where higher doses are commonly used. This may be the case for ziprasidone as well...
  37. ncbi Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder
    Menahem I Krakowski
    Nathan Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
    Arch Gen Psychiatry 63:622-9. 2006
    ..Violent behavior of patients with schizophrenia prolongs hospital stay and interferes with their integration into the community. Finding appropriate treatment of violent behaviors is of primary importance...
  38. ncbi Antipsychotic-induced weight gain and therapeutic response: a differential association
    Pal Czobor
    Nathan S Kline Institute for Psychiatric Research, Orangeburg, New York 10962, USA
    J Clin Psychopharmacol 22:244-51. 2002
    ..These findings suggest that patients who are likely to have the maximal benefits of olanzapine or clozapine treatment for symptom alleviation are at the highest risk of a clinically significant increase in weight gain...
  39. ncbi Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients
    Leslie Citrome
    Nathan S Kline Institute for Psychiatric Research, Orangeburg, New York 10962, USA
    Psychiatr Serv 55:1006-13. 2004
    ....
  40. ncbi The promise of atypical antipsychotics: fewer side effects mean enhanced compliance and improved functioning
    Leslie Citrome
    Nathan S Kline Institute for Psychiatric Research, Orangeburg, New York 10962, USA
    Postgrad Med 116:49-51, 55-9, 63. 2004
    ..In this article, the authors discuss the advantages and side effects of these agents and present a guide to help physicians choose the optimal drug in the most favorable formulation for each patient...
  41. ncbi New treatments for agitation
    Leslie Citrome
    S Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
    Psychiatr Q 75:197-213. 2004
    ..This includes newer formulations of novel antipsychotics such as liquids and rapidly disintegrating tablets, as well as intramuscular preparations...
  42. ncbi Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol
    Jan Volavka
    Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10982, USA
    J Clin Psychopharmacol 24:225-8. 2004
    ..Clozapine appears to have superior antiaggresive effects in treatment-resistant patients; this superiority develops after the patient has been exposed to an adequate dose regimen...
  43. ncbi Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia
    Jean Pierre Lindenmayer
    Nathan Kline Institute, Orangeburg, N Y, USA
    J Clin Psychiatry 65:551-6. 2004
    ..We are exploring whether this expanded clinical efficacy can also be seen in patients with treatment-resistant schizophrenia...
  44. ncbi A study of the safety, efficacy, and tolerability of switching from the standard delayed release preparation of divalproex sodium to the extended release formulation in patients with schizophrenia
    Leslie Citrome
    Nathan S Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA
    J Clin Psychopharmacol 24:255-9. 2004
    ....
  45. ncbi COMT158 polymorphism and hostility
    Jan Volavka
    Nathan Kline Institute, Orangeburg, New York 10982, USA
    Am J Med Genet B Neuropsychiatr Genet 127:28-9. 2004
    ..The Met-Met homozygotes (N = 7) were found to have significantly higher levels of hostility than the other patients (N = 53). The hypothesis was thus supported. The finding should be replicated in a larger sample...
  46. ncbi Schizophrenia and valproate
    Leslie Citrome
    Nathan S Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA
    Psychopharmacol Bull 37:74-88. 2003
    ..It is anticipated that future research will focus on the new extended-release formulation of divalproex that can be administered on a once-daily basis...
  47. ncbi Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone
    Leslie Citrome
    Nathan S Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA
    Psychiatr Serv 55:290-4. 2004
    ....
  48. ncbi Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol
    Jan Volavka
    Nathan Kline Institute, Orangeburg, NY 10982, USA
    J Clin Psychiatry 65:57-61. 2004
    ....
  49. ncbi Efficacy of the branched-chain amino acids in the treatment of tardive dyskinesia in men
    Mary Ann Richardson
    Division of Movement Disorders and Molecular Psychiatry, Nathan S Kine Institute for Psychiatric Research, Orangeburg, NY 10962, USA
    Am J Psychiatry 160:1117-24. 2003
    ..The efficacy of the branched-chain amino acids in the treatment of tardive dyskinesia in men with psychiatric disorders was tested...
  50. ncbi Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics
    Jean Pierre Lindenmayer
    Nathan Kline Institute fo Psychiatric Research, New York, NY 10035, USA
    Am J Psychiatry 160:290-6. 2003
    ....
  51. ncbi Atypical antipsychotics for acute agitation. New intramuscular options offer advantages
    Leslie Citrome
    Nathan S Kline Institute for Psychiatric Research, 140 Old Orangeburg Rd, Orangeburg, NY 10962, USA
    Postgrad Med 112:85-8, 94-6. 2002
    ..In addition, development of depot preparations of atypical antipsychotics is progressing rapidly. These products may further revolutionize the emergency and postemergency care of psychotic patients...
  52. ncbi Use of mood stabilizers among patients with schizophrenia, 1994-2001
    Leslie Citrome
    Nathan S. Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
    Psychiatr Serv 53:1212. 2002
  53. ncbi Optimal dosing of atypical antipsychotics in adults: a review of the current evidence
    Leslie Citrome
    Department of Psychiatry, New York University, New York, N Y, USA
    Harv Rev Psychiatry 10:280-91. 2002
    ....
  54. ncbi Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder
    Robert M Bilder
    Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
    Am J Psychiatry 159:1018-28. 2002
    ....
  55. ncbi The many faces of bipolar disorder. How to tell them apart
    Leslie Citrome
    New York University School of Medicine, New York, USA
    Postgrad Med 117:15-6, 19-23. 2005
    ..Effective pharmacotherapy and maintenance monitoring are critical in order to minimize the risk of relapse and associated disability, morbidity, and mortality...
  56. ncbi Toward convergence in the medication treatment of bipolar disorder and schizophrenia
    Leslie Citrome
    Department of Psychiatry, New York University School of Medicine, NY, USA
    Harv Rev Psychiatry 13:28-42. 2005
    ....
  57. ncbi Metabolic syndrome and cardiovascular disease
    Leslie Citrome
    New York University School of Medicine, Department of Psychiatry, and Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY, USA
    J Psychopharmacol 19:84-93. 2005
    ..Ongoing monitoring for all components of the metabolic syndrome is necessary. Individuals at high risk require multimodal interventions, including lifestyle interventions and targeted medications as appropriate...
  58. ncbi Efficacy of ziprasidone against hostility in schizophrenia: Post hoc analysis of randomized, open-label study data
    Leslie Citrome
    Nathan S Kline Institute for Psychiatric Research and the New York University School of Medicine, Orangeburg, NY 10962, USA
    J Clin Psychiatry 67:638-42. 2006
    ..The objective was to determine the effects of sequential intramuscular/oral ziprasi-done on hostility...
  59. ncbi Do guidelines for severe mental illness promote physical health and well-being?
    Leslie Citrome
    New York University School of Medicine, Department of Psychiatry, and Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY, USA
    J Psychopharmacol 19:102-9. 2005
    ....
  60. ncbi Metabolic issues in patients with severe mental illness
    Leslie Citrome
    New York University School of Medicine, Department of Psychiatry, and the Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY, USA
    South Med J 98:714-20. 2005
    ..Collaborative treatment between a psychiatrist and an endocrinologist is encouraged. The primary care physician may be required to fulfill both roles...
  61. ncbi Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder
    Jan Volavka
    Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10982, USA
    Am J Psychiatry 159:255-62. 2002
    ....
  62. ncbi Focus on the clinical ramifications of antipsychotic choice for the risk for developing type 2 diabetes mellitus
    Leslie Citrome
    New York University School of Medicine, NY, USA
    Int J Neuropsychopharmacol 8:147-51. 2005
  63. ncbi The emerging physical health challenges of antipsychotic associated hyperprolactinaemia in patients with serious mental illness
    Serdar M Dursun
    J Psychopharmacol 22:3-5. 2008
  64. ncbi The psychopharmacology of violence with emphasis on schizophrenia, part 2: long-term treatment
    Leslie Citrome
    Department of Psychiatry, New York University School of Medicine, NY, USA
    J Clin Psychiatry 68:331-2. 2007
  65. ncbi The psychopharmacology of violence with emphasis on schizophrenia, part 1: acute treatment
    Leslie Citrome
    Department of Psychiatry, New York University School of Medicine, New York, NY, USA
    J Clin Psychiatry 68:163-4. 2007
  66. ncbi Differential rates of treatment discontinuation in clinical trials as a measure of treatment effectiveness for olanzapine and comparator atypical antipsychotics for schizophrenia
    Bruce J Kinon
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    J Clin Psychopharmacol 26:632-7. 2006
    ....
  67. ncbi Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study
    Jean Pierre Lindenmayer
    Psychopharmacology Research Unit, Manhattan Psychiatric Center, Wards Island, NY 10035, USA
    J Clin Psychiatry 63:931-5. 2002
    ....
  68. ncbi Dosing of quetiapine in schizophrenia: how clinical practice differs from registration studies
    Leslie Citrome
    Nathan S Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA
    J Clin Psychiatry 66:1512-6. 2005
    ..The purpose of this article is to review the past and present dosing patterns of quetiapine for the treatment of schizophrenia...
  69. ncbi Are we treating schizophrenia effectively? Understanding the primary outcomes of the CATIE study
    William M Glazer
    Glazer Medical Solutions, Menemsha, MA, USA
    CNS Spectr 11:1-13; quiz 14. 2006
    ....
  70. ncbi Efficacy of aripiprazole against hostility in schizophrenia and schizoaffective disorder: data from 5 double-blind studies
    Jan Volavka
    The Nathan Kline Institute and New York University, 140 Old Orangeburg Road, Orangeburg, N Y 10962, USA
    J Clin Psychiatry 66:1362-6. 2005
    ..The objective was to determine the effects of aripiprazole on hostility...
  71. ncbi Ziprasidone for schizophrenia and bipolar disorder: a review of the clinical trials
    William M Greenberg
    Department of Psychiatry, New York University School of Medicine, New York, NY, USA
    CNS Drug Rev 13:137-77. 2007
    ....
  72. ncbi Early predictors of substantial weight gain in bipolar patients treated with olanzapine
    Ilya Lipkovich
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Clin Psychopharmacol 26:316-20. 2006
    ..Patients with less pronounced early weight gain might still be at risk for later SWG if they have close to normal BMI (< or =27 kg/m) at treatment initiation...
  73. ncbi Latest therapies for bipolar disorder. Looking beyond lithium
    Joseph F Goldberg
    Department of Psychiatry Research, Zucker Hillside Hospital, North Shore Long Island Jewish Health System, Glen Oaks, New York, USA
    Postgrad Med 117:25-6, 29-32, 35-6. 2005
    ..Maintenance treatments that have received FDA approval include olanzapine and lamotrigine. Off-label use of adjunctive medications may be required to target residual symptoms...
  74. ncbi Antipsychotics and hyperprolactinaemia: clinical recommendations
    Robert C Peveler
    University of Southampton, Royal South Hants Hospital, Southampton, UK
    J Psychopharmacol 22:98-103. 2008
    ..We hope it will add to the debate about this topic...
  75. ncbi The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia
    Daniel J Muller
    Neurogenetics Section, Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, 250 College Street R30, Toronto, Ont M5T 1R8, Canada
    Neurosci Lett 379:81-9. 2005
    ..Weight changes do not seem to be associated with polymorphism of the SNAP-25 gene, however, replication in independent samples is warranted...
  76. ncbi Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials
    Donald C Goff
    Massachusetts General Hospital, Harvard Medical School, 25 Staniford Street, Boston, MA 02114, USA
    J Clin Psychopharmacol 27:582-9. 2007
    ..We sought to evaluate the potential role of lamotrigine augmentation in schizophrenia patients resistant to atypical antipsychotic medication...
  77. ncbi Valproate: do formulations matter?
    Leslie Citrome
    J Clin Pharm Ther 33:457; author reply 458. 2008
  78. ncbi Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study
    Bruce J Kinon
    Eli Lilly and Company, Lilly Corporate Center, Drop Code 4133, Indianapolis, IN 46285, USA
    J Clin Psychopharmacol 28:392-400. 2008
    ....
  79. ncbi Pharmacokinetics of aripiprazole and concomitant lithium and valproate
    Leslie Citrome
    Nathan S. Kline Institute for Psychiatic Research and the Rockland Psychiatric Center, Orangeburg, NY 10962, USA
    J Clin Pharmacol 45:89-93. 2005
    ..Therapeutic doses of lithium and divalproex had no clinically significant effects on the pharmacokinetics of aripiprazole in patients with schizophrenia or schizoaffective disorder...
  80. ncbi Monotherapy versus polypharmacy for hospitalized psychiatric patients
    Leslie Citrome
    Am J Psychiatry 162:631; author reply 632-3. 2005
  81. ncbi Efficacy of clozapine, olanzapine, risperidone, and haloperidol in schizophrenia and schizoaffective disorder assessed with nurses observation scale for inpatient evaluation
    Jan Volavka
    Schizophr Res 76:127-9. 2005
  82. ncbi Dosing of second-generation antipsychotic medication in a state hospital system
    Leslie Citrome
    J Clin Psychopharmacol 25:388-91. 2005
  83. ncbi Best clinical practice with ziprasidone IM: update after 2 years of experience
    Dan L Zimbroff
    Pacific Clinical Research Medical Group, Upland, California 91786, USA
    CNS Spectr 10:1-15. 2005
    ..Additional trials of ziprasidone IM in agitated patients in a variety of clinical setting are warranted to generate comparative risk/benefit data with conventional agents and other second-generation antipsychotics...
  84. ncbi Neurocognitive correlates of the COMT Val(158)Met polymorphism in chronic schizophrenia
    Robert M Bilder
    Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
    Biol Psychiatry 52:701-7. 2002
    ....